Vera Therapeutics, Inc.
27.99USD
-1.0600 (-3.65%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VERA.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -112 | -125 | -94 | -84 | -80 | -57 | -49 | -50 |
| Net Income | -109 | -121 | -91 | -80 | -77 | -52 | -43 | -47 |
| EPS (Diluted) | -$1.52 | -$1.69 | -$1.39 | -$1.26 | -$1.20 | -$0.81 | -$0.72 | -$0.85 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)